Pmel17 Antibodies

Santa Cruz Biotechnology features a diverse variety of Pmel17 monoclonal antibodies for advanced research in the field of immunology and cancer biology. Pmel17 Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Pmel17, also known as gp100, is a melanocyte-specific protein that plays a crucial role in the development and function of melanocytes. Pmel17 has emerged as a significant target in melanoma research due to its involvement in the immune response against melanoma cells. Understanding the expression and function of Pmel17 is essential for developing targeted therapies and improving patient outcomes in melanoma treatment. Researchers worldwide utilize Pmel17 monoclonal antibodies to explore melanoma progression and metastasis. Advanced imaging techniques combined with Pmel17 monoclonal antibodies enable detailed visualization of cellular processes in melanoma development. Current investigations focus on how Pmel17 influences melanoma cell behavior and immune system interactions. Santa Cruz Biotechnology monoclonal antibodies for Pmel17 support the scientific community in advancing melanoma research and potential therapeutic developments.